Journal article
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
Abstract
Background There is crosstalk between the ANG-Tie2 and the PI3K/Akt/mTOR pathways. Combined ANG1/2 and mTOR blockade may have additive anti-cancer activity. The combination of trebananib, an inhibitor of ANG1/2-Tie2 interaction, with temsirolimus was evaluated in patients with advanced solid tumors to determine tolerability, maximum tolerated dose (MTD), and preliminary antitumor activity. Methods Patients were enrolled using 3 + 3 design, and …
Authors
Chiu JW; Hotte SJ; Kollmannsberger CK; Renouf DJ; Cescon DW; Hedley D; Chow S; Moscow J; Chen Z; Perry M
Journal
Investigational New Drugs, Vol. 34, No. 1, pp. 104–111
Publisher
Springer Nature
Publication Date
February 2016
DOI
10.1007/s10637-015-0313-8
ISSN
0167-6997